Table 1.
Population characteristics of the whole unmatched cohort
| Variable | Total (n = 5,480) | Type 1 diabetes patients (n = 72) | HCs (n = 5,408) | P‐value |
|---|---|---|---|---|
| Mean age, years (range) | 35 (26–48) | 45 (34–56) | 35 (26–48) | <0.001* |
| Sex (M : F) | 1,830:3,616 (1:1.9) | 29:43 (1:1.5) | 1,801:3,573 (1:2) | 0.227 |
| Ethnicity | ||||
| White | 2,431 (44) | 35 (48) | 2,396 (44) | 0.147 |
| African American/African origin | 36 (0.7) | 0 (0) | 36 (0.7) | |
| Asian | 1,473 (27) | 27 (37) | 1,446 (27) | |
| Hispanic | 836 (15) | 5 (7) | 836 (15) | |
| Native American/Indigenous/Pacific Islander | 29 (0.5) | 0 (0) | 29 (0.5) | |
| Do not wish to disclose | 369 (6.7) | 2 (3) | 367 (7) | |
| Other | 301 (5.5) | 3 (4) | 298 (5.5) | |
| Vaccine taken | ||||
| Pfizer‐BioNTech | 1965 (36) | 28 (39) | 1937 (36) | <0.001* |
| Oxford/AstraZeneca | 571 (10) | 6 (8) | 565 (10) | |
| Johnson & Johnson (J&J) | 46 (0.8) | 2 (3) | 44 (1) | |
| Moderna | 247 (4.5) | 1 (1.4) | 246 (4.5) | |
| Novavax | 3 (0.1) | 1 (1.4) | 2 (0) | |
| Covishield (serum institute India) | 731 (13) | 21 (29) | 710 (13) | |
| Covaxin (Bharat Biotech) | 130 (2.4) | 1 (1.4) | 129 (2.4) | |
| Sputnik | 147 (2.7) | 2 (3) | 145 (2.7) | |
| Sinopharm | 1,308 (24) | 7 (10) | 1,301 (24) | |
| I am not sure | 36 (0.7) | 1 (1.4) | 35 (0.6) | |
| Others | 294 (4.4) | 2 (3) | 294 (5.4) | |
The χ2‐test and Mann–Whitney U‐test were carried out.
*
P < 0.05 significant.
F, female; HCs, healthy controls; M, male.